Profile data is unavailable for this security.
About the company
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
- Revenue in USD (TTM)0.00
- Net income in USD-106.03m
- Incorporated1998
- Employees30.00
- LocationCassava Sciences Inc6801 N. Capital of Texas HighwayBuilding 1AUSTIN 78731United StatesUSA
- Phone+1 (512) 501-2444
- Fax+1 (512) 614-0414
- Websitehttps://www.cassavasciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precision BioSciences Inc | 698.00k | -83.60m | 90.67m | 67.00 | -- | 2.88 | -- | 129.91 | -8.40 | -8.40 | 0.0695 | 1.38 | 0.0057 | -- | 0.9001 | 6,462.96 | -67.76 | -26.22 | -76.07 | -33.68 | -- | -- | -11,977.36 | -87.80 | -- | -190.84 | 0.5736 | -- | 40.98 | 25.30 | 116.85 | -- | -59.31 | -- |
| Incannex Healthcare Inc | 12.00k | -47.87m | 93.13m | 12.00 | -- | 1.21 | -- | 7,761.22 | -0.9375 | -0.9375 | 0.0001 | 0.2215 | 0.0003 | -- | 0.0015 | 1,000.00 | -101.03 | -155.80 | -114.13 | -186.20 | -- | -- | -398,933.30 | -6,230.96 | -- | -43.84 | 0.00 | -- | 616.67 | -31.02 | -154.00 | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -10.93m | 93.80m | 4.00 | -- | 6.12 | -- | -- | -0.3369 | -0.3369 | 0.00 | 0.4593 | 0.00 | -- | -- | 0.00 | -58.55 | -47.85 | -62.09 | -49.81 | -- | -- | -- | -8,381.30 | -- | -- | 0.00 | -- | -- | -- | 12.96 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -27.99m | 94.45m | 25.00 | -- | 2.59 | -- | -- | -0.4816 | -0.4816 | 0.00 | 0.4138 | 0.00 | -- | -- | 0.00 | -78.86 | -59.00 | -108.44 | -75.05 | -- | -- | -- | -- | -- | -3,450.08 | 0.00 | -- | -- | -- | -31.73 | -- | -51.16 | -- |
| Equillium Inc | 4.39m | -24.42m | 97.43m | 35.00 | -- | 3.14 | -- | 22.18 | -0.632 | -0.632 | 0.1021 | 0.5099 | 0.1274 | -- | 1.71 | 125,485.70 | -70.81 | -44.86 | -89.09 | -58.85 | -- | -- | -555.94 | -164.30 | -- | -- | 0.00 | -- | 13.89 | -- | 39.51 | -- | 2.81 | -- |
| Artiva Biotherapeutics Inc | 0.00 | -79.19m | 97.93m | 106.00 | -- | 0.7579 | -- | -- | -3.25 | -3.25 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -42.29 | -44.57 | -45.24 | -51.09 | -- | -- | -- | -596.66 | -- | -- | 0.0006 | -- | -99.25 | -- | -127.62 | -- | 18.74 | -- |
| Actuate Therapeutics Inc | 0.00 | -24.12m | 98.55m | 10.00 | -- | 9.01 | -- | -- | -1.19 | -1.19 | 0.00 | 0.4705 | 0.00 | -- | -- | 0.00 | -150.86 | -- | -282.00 | -- | -- | -- | -- | -- | -- | -- | 0.0357 | -- | -- | -- | -10.27 | -- | -- | -- |
| Cassava Sciences Inc | 0.00 | -106.03m | 99.03m | 30.00 | -- | 1.21 | -- | -- | -2.20 | -2.20 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -59.99 | -28.22 | -85.37 | -29.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 74.96 | -- | 41.75 | -- |
| Agenus Inc | 106.83m | -35.38m | 103.00m | 316.00 | -- | -- | -- | 0.9642 | -2.09 | -2.09 | 3.94 | -8.35 | 0.4523 | -- | 286.79 | 338,066.50 | -16.63 | -58.29 | -- | -140.29 | 98.93 | 97.31 | -36.77 | -125.67 | -- | -1.17 | 6.78 | -- | -33.81 | -7.17 | 7.54 | -- | -34.16 | -- |
| Goldenwell Biotech Inc | 62.50k | -75.13k | 103.95m | -- | -- | -- | -- | 1,663.20 | -0.0007 | -0.0007 | 0.0006 | -0.001 | 0.3126 | 0.00 | -- | -- | -37.58 | -95.49 | -41.82 | -110.12 | 100.00 | 52.18 | -120.21 | -2,064.27 | 1.16 | -4.11 | 124.14 | -- | -92.39 | -13.55 | -12.05 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | -24.76m | 104.16m | -- | -- | 2.20 | -- | -- | -0.3400 | -0.3400 | 0.00 | 0.5372 | 0.00 | -- | -- | -- | -26.72 | -- | -48.02 | -- | -- | -- | -- | -- | 0.1062 | -129.48 | 0.0781 | -- | -- | -- | -17.08 | -- | -- | -- |
| Immunic Inc | 0.00 | -103.05m | 104.66m | 91.00 | -- | 8.18 | -- | -- | -0.8362 | -0.8362 | 0.00 | 0.1064 | 0.00 | -- | -- | 0.00 | -195.41 | -83.24 | -396.11 | -96.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.37 | -- | 36.85 | -- |
| Turn Therapeutics Inc | -100.00bn | -100.00bn | 105.56m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cardiff Oncology Inc | 501.00k | -50.45m | 106.43m | 32.00 | -- | 2.17 | -- | 212.43 | -0.7976 | -0.7976 | 0.0079 | 0.7272 | 0.0079 | -- | 1.15 | 15,656.25 | -79.61 | -32.23 | -101.41 | -34.83 | -- | -- | -10,064.27 | -7,588.71 | -- | -- | 0.00 | -- | 39.96 | 22.80 | -9.62 | -- | 3.42 | -- |
| Codexis Inc | 52.93m | -63.95m | 106.58m | 188.00 | -- | 2.76 | -- | 2.01 | -0.7514 | -0.7514 | 0.6238 | 0.4269 | 0.389 | 5.42 | 4.03 | 281,553.20 | -47.00 | -21.95 | -58.53 | -26.20 | 79.31 | 76.67 | -120.82 | -49.88 | 4.02 | -- | 0.5076 | -- | -15.39 | -2.82 | 14.38 | -- | 2.91 | -- |
| MacroGenics Inc | 127.63m | -75.89m | 108.17m | 341.00 | -- | 1.61 | -- | 0.8476 | -1.21 | -1.21 | 2.02 | 1.06 | 0.4769 | 5.23 | 3.27 | 374,266.90 | -28.36 | -33.40 | -35.18 | -40.60 | 75.41 | -- | -59.46 | -97.17 | 5.02 | -26.97 | 0.5119 | -- | 155.26 | 18.50 | -639.30 | -- | -2.88 | -- |
Data as of Feb 12 2026. Currency figures normalised to Cassava Sciences Inc's reporting currency: US Dollar USD
19.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.06m | 4.28% |
| Marshall Wace LLPas of 30 Sep 2025 | 2.06m | 4.27% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.40m | 2.90% |
| Two Sigma Advisers LPas of 30 Sep 2025 | 961.50k | 1.99% |
| JPMorgan Securities LLC (Investment Management)as of 30 Sep 2025 | 565.44k | 1.17% |
| Two Sigma Investments LPas of 30 Sep 2025 | 565.00k | 1.17% |
| Geode Capital Management LLCas of 30 Sep 2025 | 537.90k | 1.11% |
| GMT Capital Corp.as of 30 Sep 2025 | 450.10k | 0.93% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2025 | 439.83k | 0.91% |
| 683 Capital Management LLCas of 30 Sep 2025 | 425.00k | 0.88% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
